05 Dec 2023
byNatalia Reoutova
Selpercatinib, a selective RET kinase inhibitor, showed superior efficacy vs chemotherapy and pembrolizumab as first-line (1L) treatment in patients with stage IIIB–IV nonsquamous non-small-cell lung cancer (NSCLC) with RET gene fusions, according to results of the open-label phase III LIBRETTO-431 study presented at the European Society for Medical Oncology Congress 2023 (ESMO 2023).